~~<i id='B4699A25D5'><strike id='B4699A25D5'><tt id='B4699A25D5'><pre id='B4699A25D5'></pre></tt></strike></i>~~

Home» Wikipedia» focus

focus

author：focus 2025-09-27 18:44:19 Page View：4

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Solve the antibiotic resistance crisis with preventive drugs
Next article： Moonlake's readout produced a cash windfall. Risks remain

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Pharmacists can make shortage drugs, but at what cost?

AdobePharmacistsincreasinglyarebeingaskedtomakedrugsinbulkforhospitalsthatareinshortsupply,andthey’r

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

FDA warns J&J's Abiomed: We will regulate your software

Abiomed,whichwasboughtbyJohnson&Johnsonlatelastyearfor$16.6billion,sellsdevicesforheartfailurepa